Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29749910 | 0.82 | L3MBTL1 (0.73) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL9171144 | 0.81 | MGLL (0.50) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL7754070 | 0.80 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1FGFR1KDM4EFAAH | |
| SCHEMBL1728478 | 0.79 | MGLL (0.67) | ALDH1A1FGFR1PKMFAAHMGLL | |
| SCHEMBL18367729 | 0.79 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2FGFR1 | |
| SCHEMBL22236845 | 0.76 | CA12 (0.52) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL2518610 | 0.76 | ALDH1A1 (0.59) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL28257396 | 0.75 | ALDH1A1 (0.54) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3791105 | 0.75 | KMT2A (0.66) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6798021 | 0.73 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2021-01-28 | — | — | US | claimed |
| EP-2727606-A2 | Compounds for killing psma-expressing, taxane-resistant cancer cells | Psma Development Company, L.L.C. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-1912677-B1 | PSMA antibody-drug conjugates | PSMA DEV COMPANY L L C (US) | 2013-10-02 | — | — | EP | claimed |
| EP-2326350-B1 | COMPOUNDS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEV COMPANY L L C (US) | 2013-09-04 | — | — | EP | claimed |
| EP-1718667-B1 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2013-01-09 | — | — | EP | claimed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | claimed |
| US-7754681-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2010-07-13 | — | — | US | claimed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| EP-1718667-A4 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2009-04-08 | — | — | EP | claimed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1718667-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | SEAGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005082023-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
| EP-3827844-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | Psma Development Company, L.L.C. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20070160617-A1 | PSMA antibody-drug conjugates | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | FOLH1, PSMA3, PSMA2 | L3MBTL1 1683/4885ALDH1A1 2734/4885KMT2A 411/4885 |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | L3MBTL1 892/4885ALDH1A1 2008/4885KMT2A 4159/4885 |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | CTSS, CTSE, CTSL | L3MBTL1 1587/4885ALDH1A1 2102/4885KMT2A 4454/4885 |
| US-20070160617-A1 | PSMA antibody-drug conjugates | FOLH1, PSMA3, PSMA2 | L3MBTL1 1683/4885ALDH1A1 2734/4885KMT2A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.